CDK4 and thyroid gland carcinoma: Thus, inhibition of ERK pathway synergizes with CDK4/6i, potentiating the proliferation-suppressive properties of each of the drugs and strongly impairing the long-term growth of thyroid cancer cells and the development of resistance.